A 56-week long clinical trial using orally administered faecal microbiota transplantation (FMT) has led to remission in patients suffering from active ulcerative colitis.
Australia’s Therapeutic Goods Administration (TGA) is drafting a new regulation which will govern the manufacturing process and uses of faecal microbiota transplant (FMT) products.